Leucine, which provides digital twins to help pharmaceutical companies meet compliance needs , raised USD 7 million in a Series A funding round led by Ecolab with participation from existing investors including Pravega Ventures and Axilor Ventures. This brings the total funds raised by the company to USD 8.1 million.

The new funds will be used to enhance the company’s AI-powered digital twin platform for drug manufacturers. Additionally, the funding will facilitate the company's expansion to serve more facilities and customers.

Leucine provides a digital platform that automates compliance management and manufacturing record creation for pharmaceutical manufacturers using AI. The platform enables the creation of digital twins to analyze deviations, offer real-time performance monitoring, and transform paper-based data into digital format to significantly streamline the digitization process. As of October 2023, the company’s compliance cloud platform is used by 30+ companies in more than 300 pharmaceutical manufacturing facilities across 10 countries.